Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase III trial of high-dose chemotherapy plus autologous stem cell transplantation versus consolidating conventional chemotherapy in primary CNS lymphoma
2012-000620-17Phase 3Completed
- Sponsor
- Landeshauptstadt Stuttgart
- Start
- Feb 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab, methotrexate, cytarabine, thiotepa, carmustine and 5 more in primary central nervous system lymphoma (PCNSL) and diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Landeshauptstadt Stuttgart. Primary endpoint: Progression-free survival. Started Feb 2014; status: completed.
02
Drugs
rituximabmethotrexatecytarabinethiotepacarmustine
03
Conditions
primary central nervous system lymphoma (PCNSL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2012-000620-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000620-17.